Side-by-side comparison of AI visibility scores, market position, and capabilities
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Lausanne Switzerland automated cloud lab for AI protein engineering at $11.2M total ($8M ACE Ventures seed 2025); improved protein success rate from 2.5% to 13% testing 10K+ proteins for 30+ pharma/biotech partners competing with Recursion for AI drug discovery.
Adaptyv Biosystems is a Lausanne, Switzerland-based AI-driven protein engineering platform — backed with $11.2 million in total funding including an $8 million seed round in 2025 led by ACE Ventures with participation from ByFounders, Founderful, and LongGame Ventures, following a CHF 2.5 million pre-seed in 2022 — providing pharmaceutical companies, biotechnology firms, and academic AI research groups with fully automated cloud laboratory services for validating and iterating AI-generated protein designs, enabling the experimental testing that transforms computational protein engineering from theoretical exploration to practical drug discovery. Founded in 2021 and having tested over 10,000 proteins in collaboration with 30+ pharma and biotech partners, Adaptyv has improved protein engineering success rates from the industry baseline of 2.5% to 13% — a 5x improvement that represents the breakthrough enabling practical AI-guided therapeutic protein development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.